Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Reply
Rheumatology (Oxford). 2024 May 13:keae261.
doi: 10.1093/rheumatology/keae261.
Online ahead of print.